Addex Therapeutics Ltd - ADR
ADXN
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.73M
Close$
$2.09
40.7% downside
Current Fair Value
40.7% downsideOvervalued by 40.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.73 Million |
|---|---|
| Enterprise Value | $3.93 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.88 |
| Beta | 2 |
| Outstanding Shares | 1,427,000 |
Return
| Return on Equity | -211.58% |
|---|---|
| Return on Assets | -146.12% |
| Return on Invested Capital | -131.97% |
Valuation & Multiples
| P/E Ratio | -0.52 |
|---|---|
| PEG | -3.22 |
| Price to Sales | - |
| Price to Book Ratio | 1.76 |
| Enterprise Value to Revenue | 18.13 |
| Enterprise Value to EBIT | -0.84 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Addex Therapeutics Ltd
27 employees
CEO: Tim Dyer